Latest News

Influenza has claimed more Australian lives in the first seven months of 2025 than during the same period in the severe flu season of 2019, prompting urgent calls for greater investment in nurse-led vaccination programs.

Executive chairman Paul Hopper authorised the announcement, noting that Radiopharm’s strategy is to develop a differentiated platform of radiopharmaceutical products across peptides, small molecules, and antibodies.

Australian motion technology company dorsaVi (ASX:DVL) has announced a technical milestone that could reshape the future of robotics and human–machine interaction.

After more than a decade of debate and indecision, the New Zealand Government has unveiled a new framework for procuring hospital medical devices, promising greater efficiency, certainty, and transparency for suppliers, clinicians, and patients.

Australian company INOVIQ (ASX:IIQ) has unveiled new peer-reviewed data validating its proprietary exosome-based cancer platform, positioning the company at the forefront of next-generation cell-free therapies.

The Gold Coast has secured a significant foothold in the global race for personalised medicine, with the arrival of Southern RNA and its international partner, Providence Therapeutics, at the Gold Coast Health and Knowledge Precinct.

President Donald J. Trump has signed a new Executive Order aimed at harnessing artificial intelligence to accelerate progress against paediatric cancer.

With the listing of Sandoz’s ERELZI (etanercept) on the PBS from today, Australia gains another biosimilar option in a therapeutic class that has shaped two decades of policy debate around access, cost, and sustainability.

Australia’s advanced therapies sector is poised for a new chapter of coordination and leadership, with AusBiotech and MA today launching an expression of interest for members to join the newly established Advanced Therapies Advisory Group.

Medical Affairs has become one of the most strategically essential functions in the life sciences sector, bridging science, clinical practice, industry, and patient need.

Australian-based pharmaceutical companies have begun submitting higher reimbursement prices in applications to the PBAC, with some explicitly using US list prices, while Pfizer has announced an agreement with the Trump administration "that will ensure US patients pay lower prices".

In the third and final part of our series on the challenge of institutional rigidity, we explore the exceptionalism in health technology decision-making, its implications for patients, and the most compelling argument for meaningful change, rooted in a 900-year-old principle.